Studies have provided evidence that JSI-124 treatment effectively induces apoptosis in glioblastoma cells by activating the bcl-2 family proteins, which play a crucial role in promoting apoptosis and underscore JSI-124 potential as a glioblastoma-targeting therapeutic agent [18]. Here, BCL2 is linked to glioblastoma.